Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Urine Liquid Biopsy Test Detects Molecular Evidence of Prostate Cancer

By LabMedica International staff writers
Posted on 29 Mar 2022

A standalone, non-invasive liquid biopsy urine test can, from a single urine specimen, accurately detect molecular evidence of prostate cancer and, if cancer is detected, classify the severity, or the risk grade, of the malignancy. More...

The miR Sentinel Prostate Cancer Test from miR Scientific, LLC (New York, NY, USA) uses proprietary high-throughput technology based on the interrogation of small noncoding RNAs (sncRNAs) extracted from urinary exosomes. The highly accurate, easy-to-administer miR Sentinel Prostate Cancer Test is powered by the miR Disease Management Platform, the company’s proprietary, non-invasive algorithm-based platform for the effective management of targeted diseases, initially focused on urological cancers. The platform uses precise biologic information interrogation techniques to categorize patients into one of four groups: no cancer, low-risk cancer, intermediate-risk cancer, or high-risk cancer. This gives physicians the ability to clearly determine which patients need treatment and which can be safely and non-invasively monitored, helping avoid harmful and costly overtreatment.

One urine sample is all that’s required for the test to accurately diagnose and classify prostate cancer with 95% sensitivity and specificity, thereby avoiding the standard invasive and inaccurate screening procedures. The test was shown in clinical studies to detect and classify clinically significant prostate cancer with over 90% accuracy. Based on these results, the U.S. Food & Drug Administration has granted the test a Breakthrough Device Designation. When comparing the results of the miR Sentinel Prostate Cancer Test to systematic core needle biopsy in men presenting with initial suspicion of prostate cancer, the latest validation study demonstrated a 93% concordance between the two methods of screening and detection regarding the classification of clinically significant cancer.

"We believe that the accuracy, accessibility, and non-invasive features of our award-winning technology will impact the lives of millions of men and forever positively evolve the standard of care for urological cancers," said Sam Salman, Chairman and CEO of miR Scientific.

Related Links:
miR Scientific, LLC 


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
New
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.